BIOBIZKAIA HEALTH RESEARCH INSTITUTE (IIS BIOBIZKAIA)
Period of enjoyment: From September 2025 to May 2026.
Biobizkaia Health Research Institute is a Health Research Institute of Bizkaia Region. It was established in 2008 and it aims to promote, unite and support the research groups to develop a quality translational research and enhance the effective innovation and collaboration with other organizations; all this in order to provide new tools, practices, and knowledge to contribute to the improvement of health care, population health, wealth creation, and economic development. Five important organisations in the Basque Country (Health Department of the Basque Government, Public Health Provider Organization (OSA), Basque Public University and Basque Foundation for Health Innovation and Research (BIOEF) and Foundation BBK.
The legal agreement between IIS Biobizkaia and the Basque Health System in fact provides the framework for the cooperation between the two institutions, with the goal of translating research results into medical practice. There are close to 900 professionals with complementary basic and clinical profiles divided into more than 60 research groups. BBHRI is taking part in close to 150 clinical trials and offers a long-running close relationship with the University of the Basque Country and other hospitals of the Basque Country.
Research proposals must be related to the “Biomedical engineering, Bioprinting and 3D” research group, led by Dr. Isabel Andia. This group works on the following areas:
- Autologous therapies (PRP) in joint pathologies: osteoarthritis and chondroplasties.
- Autologous therapies (PRP) in tendon pathology.
- Cell therapy in joint and tendon pathology: mesenchymal fat cells Biology of platelet-rich plasmas (PRPs).
- Modulating effect of PRP on inflammation.
- Modulating effect of PRP on angiogenesis.
- Effect of PRP on cell activation (fat mesenchymal, tendon cells, synovial cells).
- Study of immunohistochemically, genetic and molecular cytogenetic markers in biopsies from patients with soft tissue sarcomas: diagnostic utility, relationship with prognosis and applicability in the monitoring of minimal residual disease.
- Prevention of postoperative bleeding in massive resection surgery of bone tumors: Multicenter, randomized, open-label, parallel clinical trial with three treatment arms, evaluating the efficacy of topical tranexamic acid versus topical Evicel® and usual hemostasis.
To obtain the proposal’s approval, please email: IRATXE.CIRIZAERENO@bio-bizkaia.eus
Location: Plaza Cruces S/N, 48903 Barakaldo, Spain.
Webpage: https://www.biocrucesbizkaia.org
*ISS Biobizkaia offers support in finding accommodation, only for the selected candidate, in the researchers’ residential buildings of Bizkaia Talent: BBK Talent Home. Those that deny this option must secure their own option for accommodation and inform both parties, at least, 1 month before arrival in Spain.